BioWorld. Link to homepage.

Clarivate
  • BioWorld
  • BioWorld MedTech
  • BioWorld Asia
  • BioWorld Science
  • Data Snapshots
    • BioWorld
    • BioWorld MedTech
    • Infographics: Dynamic digital data analysis
    • Index insights
    • NME Digest
  • Special reports
    • Infographics: Dynamic digital data analysis
    • Trump administration impacts
    • Under threat: mRNA vaccine research
    • BioWorld at 35
    • Biopharma M&A scorecard
    • Bioworld 2025 review
    • BioWorld MedTech 2025 review
    • BioWorld Science 2025 review
    • Women's health
    • China's GLP-1 landscape
    • PFA re-energizes afib market
    • China CAR T
    • Alzheimer's disease
    • Coronavirus
    • More reports can be found here

BioWorld. Link to homepage.

  • Sign In
  • Sign Out
  • My Account
Subscribe
BioWorld - Friday, December 26, 2025
Home » Newsletters » BioWorld Science

BioWorld Science

April 2, 1998

View Archived Issues

Company Profile: IgX

Read More

New compounds synthesized at HMR upregulate LDL receptors

Read More

Schering-Plough presents new agents for cognitive disorders

Read More

Recent data suggest mechanism of action of nefiracetam's beneficial effects on cognition

Read More

Genentech receives fast track product designation for Herceptin

Read More

Novel liposomal delivery system available for licensing from NCI/NIH

Read More

MGI Pharma presents MGI-114 data at AACR

Read More

BioTime files NDA for blood plasma volume expander

Read More

Nefiracetam: a potential treatment for PCP addiction?

Read More

TAPET efficacy reported at AACR meeting

Read More

Dramatic anticancer activity observed with FGN-1 in animal models

Read More

Broad-spectrum antibacterial agents synthesized by Daiichi

Read More

MGI now distributing Salagen for Sjogren's syndrome in U.S.

Read More

Mochida prepares novel agents for disorders associated with eosinophilia

Read More

Banyu develops factor Xa inhibitors as antiplatelet/antithrombotic agents

Read More

Cardioprotective effects of new Lederle compound assessed

Read More

Merck KGaA initiates worldwide cancer study with BEC2

Read More

TheraTech, Palatin collaborate on oral peptides; first product will be a new treatment for ED

Read More

Preclinical data indicates efficacy of AltaRex's approach to cancer immunotherapy

Read More

Neurex completes patient enrollment in ziconotide phase III trial

Read More

Protein farnesyltransferase inhibitor advanced to clinical trials by Schering-Plough

Read More

Liposomal telomerase antisense oligonucleotide effective alone and in combination

Read More

Chiron obtains full ownership of Chiron Behring

Read More

Merck & Co. identifies orally active, short-acting GH secretatogue

Read More

Research at Pfizer leads to potent CysLT1 antagonist

Read More

N-Alkylated saccharins from Merck & Co. with potential in BPH therapy

Read More

NTE-122: effects on lipid metabolism and secretion in vitro

Read More

GH secretagogue shows beneficial cardiovascular activity in rats

Read More

Mechanism of vasorelaxant effects of HFV-1017C elucidated

Read More

FR-146801 inhibits intimal thickening in a rat balloon injury model

Read More

Popular Stories

  • Today's news in brief

    BioWorld
    BioWorld briefs for Dec. 24, 2025.
  • Today's news in brief

    BioWorld MedTech
    BioWorld MedTech briefs for Dec. 24, 2025.
  • Illustration of magnifying glass looking at cancer in the brain

    Researchers discover how glioblastoma tumors dodge chemotherapy

    BioWorld MedTech
    Researchers at the University of Sydney have uncovered a mechanism that may explain why glioblastoma returns after treatment, and the world-first discovery offers...
  • Left: Anthony Fauci. Right: Transmission electron micrograph of HIV-1 virus particles

    HIV research is close to a cure but far from ending the pandemic

    BioWorld
    Advances in antiretroviral therapy (ART) now allow people living with HIV to lead normal lives with undetectable and nontransmissible levels of the virus in their...
  • Illustration of tau accumulating in a neuron cell.

    ADEL wins $1.04B Sanofi deal for tau-targeting Alzheimer’s drug

    BioWorld
    ADEL Inc. closed a year-end licensing deal worth up to $1.04 billion with Sanofi SA for ADEL-Y01, a specific tau-targeting Alzheimer’s disease drug candidate in a...
  • BioWorld
    • Today's news
    • Analysis and data insight
    • Clinical
    • Data Snapshots
    • Deals and M&A
    • Financings
    • Newco news
    • Opinion
    • Regulatory
    • Science
  • BioWorld MedTech
    • Today's news
    • Clinical
    • Data Snapshots
    • Deals and M&A
    • Financings
    • Newco news
    • Opinion
    • Regulatory
    • Science
  • BioWorld Asia
    • Today's news
    • Analysis and data insight
    • Australia
    • China
    • Clinical
    • Deals and M&A
    • Financings
    • Newco news
    • Regulatory
    • Science
  • BioWorld Science
    • Today's news
    • Biomarkers
    • Cancer
    • Conferences
    • Endocrine/Metabolic
    • Immune
    • Infection
    • Neurology/Psychiatric
    • NME Digest
    • Patents
  • More
    • About
    • Advertise with BioWorld
    • Archives
    • Article reprints and permissions
    • Contact us
    • Cookie policy
    • Copyright notice
    • Data methodology
    • Infographics: Dynamic digital data analysis
    • Index insights
    • Podcasts
    • Privacy policy
    • Share your news with BioWorld
    • Staff
    • Terms of use
    • Topic alerts
Follow Us

Copyright ©2025. All Rights Reserved. Design, CMS, Hosting & Web Development :: ePublishing